Published in Int J Clin Exp Med on November 15, 2015
Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice. Clin Mol Allergy (2016) 0.76
The asthma epidemic. N Engl J Med (2006) 8.60
Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46
IL-17: prototype member of an emerging cytokine family. J Leukoc Biol (2002) 4.39
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol (2002) 3.71
Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science (1994) 3.57
Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem (2003) 3.39
Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest (1999) 3.32
IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res (2006) 2.66
Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol (2001) 2.39
Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med (2003) 2.26
Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol (2007) 2.05
Th17 and allergy. Allergol Int (2008) 1.80
House dust mite allergens in asthma and allergy. Trends Mol Med (2010) 1.68
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy (2002) 1.63
From allergen genes to allergy vaccines. Annu Rev Immunol (2010) 1.46
IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol (2006) 1.29
Free, soluble interleukin-17 protein during severe inflammation in human airways. Eur Respir J (2002) 1.27
Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy (2010) 1.20
Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy (2004) 1.15
Oral Bromelain Attenuates Inflammation in an Ovalbumin-induced Murine Model of Asthma. Evid Based Complement Alternat Med (2008) 1.01
Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma. Chin Med J (Engl) (2005) 1.01
Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol (2007) 0.97
Characterization of T-cell responses to the house dust mite allergen Der p II in mice. Evidence for major and cryptic epitopes. Immunology (1993) 0.96
Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine (2009) 0.96
Interleukin-4 and its receptor: essential mediators of the allergic response. J Allergy Clin Immunol (1997) 0.95
Inhibition of T-cell responses by feeding peptides containing major and cryptic epitopes: studies with the Der p I allergen. Immunology (1994) 0.91
IL-10 induces a Th2 cell tolerance in allergic asthma. Int Arch Allergy Immunol (1999) 0.91
Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol (2012) 0.87
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy (2010) 0.85
Allergen immunotherapy: therapeutic vaccines for asthma. Clin Allergy Immunol (2004) 0.78